Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 13/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 11/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.42 |
| ▸ | GABRE | P78334 | 1/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.42 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.42 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6061090 | 0.85 | HSD17B1 (0.52) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL3022644 | 0.85 | ALOX5 (0.42) | TSHRESR2ALOX5CHRNB4CHRNA3 | |
| SCHEMBL1116711 | 0.79 | CYP1A2 (0.41) | TSHRCYP3A4CYP1A2ALDH1A1LMNA | |
| SCHEMBL4284340 | 0.79 | HSD17B1 (0.49) | HSD17B1HSD17B2CYP3A4CYP2C9GABRP | |
| SCHEMBL4279134 | 0.79 | ACHE (0.50) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL2012652 | 0.79 | GABRP (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8506859 | 0.79 | GABRP (0.42) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL16720513 | 0.76 | HSD17B1 (0.42) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL5106003 | 0.76 | MAPT (0.41) | TSHRCYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL6969894 | 0.76 | HSD17B1 (0.50) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2397462-A2 | Compounds, compositions and methods of treatment for heart failure | Cytokinetics, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20090176307-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-7491826-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7399866-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20060241110-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-10-26 | — | — | US | disclosed |
| US-20050159416-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241110-A1 | Compounds, compositions, and methods | TNNI3, TNNT2, TNNC1 | TSHR 4482/4885HSD17B1 4412/4885HSD17B2 4480/4885 |
| US-20050159416-A1 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | TSHR 4548/4885HSD17B1 4420/4885HSD17B2 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.